Meeder Asset Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $4.35K | Buy |
|
|||||
|
2025
Q2 | $3.39K | Buy |
|
|||||
|
2025
Q1 | $2.65K | Sell |
|
|||||
|
2024
Q4 | $5.6K | Buy |
|
|||||
|
2024
Q3 | $4.61K | Sell |
|
|||||
|
2024
Q2 | $6.61K | Hold |
|
|||||
|
2024
Q1 | $6.62K | Buy |
|
|||||
|
2023
Q2 | – | Sell |
|
|||||
|
2023
Q1 | $10.1K | Sell |
|
|||||
|
2022
Q4 | $147K | Sell |
|
|||||
|
2022
Q3 | $469K | Buy |
|
|||||
|
2022
Q2 | $17K | Sell |
|
|||||
|
2022
Q1 | $19K | Buy |
|
|||||
|
2021
Q4 | – | Sell |
|
|||||
|
2021
Q3 | $48K | Buy |
|
|||||
|
2021
Q2 | $9K | Sell |
|
|||||
|
2021
Q1 | $496K | Buy |
|
|||||
|
2020
Q4 | $2K | Sell |
|
|||||
|
2020
Q3 | $818K | Sell |
|
|||||
|
2020
Q2 | $1.12M | Sell |
|
|||||
|
2020
Q1 | $878K | Buy |
|
|||||
|
2019
Q4 | $650K | Buy |
|
|||||
|
2019
Q3 | $441K | Buy |
|
|||||
|
2019
Q2 | $1K | Buy |
|
|||||
|
2019
Q1 | – | Sell |
|
|||||
|
2018
Q4 | $427K | Buy |
|
|||||
|
2018
Q3 | $131K | Sell |
|
|||||
|
2018
Q2 | $110K | Buy |
|
|||||
|
2018
Q1 | $13K | Buy |
|
|||||
|
2017
Q4 | $10K | Buy |
|
|||||
|
2017
Q3 | $5K | Sell |
|
|||||
|
2017
Q2 | $6K | Buy |
|
|||||
|
2016
Q4 | – | Sell |
|
|||||
|
2016
Q3 | $57K | Buy |
|
|||||
|
2016
Q2 | $7K | Sell |
|
|||||
|
2016
Q1 | $152K | Sell |
|
|||||
|
2015
Q4 | $1.39M | Buy |
|
|||||
|
2015
Q3 | – | Sell |
|
|||||
|
2015
Q2 | $2.66M | Buy |
|